Cryptogenic Stroke in the Young: Role of Candidate Gene Polymorphisms in Indian Patients with Ischemic Etiology

Innovative percutaneous procedures for stroke prevention have emerged in the last two decades. Transcatheter closure of the patent foramen ovale (PFO) is performed in patients who suffered a cryptogenic stroke or a transient ischaemic attach (TIA) in order to prevent recurrence of thromboembolic events. Percutaneous occlusion of the left atrial appendage (LAA) has been introduced to reduce stroke risk in patients with atrial fibrillation (AF). The role of PFO and LAA in the occurrence of cerebrovascular events and the interventional device-based therapies to occlude the PFO and LAA are discussed.

Download Full-text

Patent Foramen Ovale, the Role of Antiplatelet Therapy Alone or Anticoagulant Therapy Alone Versus Device Closure for Cryptogenic Stroke: A Review of the Literature and Current Recommendations

Cardiovascular & Hematological Agents in Medicinal Chemistry ◽

10.2174/1871525718666200203111641 ◽

2020 ◽

Vol 18 (2) ◽

pp. 135-150

Author(s):

Harsha S. Nagarajarao ◽

Chandra P. Ojha ◽

Archana Kedar ◽

Debabrata Mukherjee

Keyword(s):

Patent Foramen Ovale ◽

Cryptogenic Stroke ◽

Narrow Channel ◽

Paradoxical Embolism ◽

Current Evidence ◽

Foramen Ovale ◽

The Right ◽

The Relationship ◽

Current Guidelines

: Cryptogenic stroke and its relation to the Patent Foramen Ovale (PFO) is a long-debated topic. Recent clinical trials have unequivocally established the relationship between cryptogenic strokes and paradoxical embolism across the PFO. This slit-like communication exists in everyone before birth, but most often closes shortly after birth. PFO may persist as a narrow channel of communication between the right and left atria in approximately 25-27% of adults. : In this review, we examine the clinical relevance of the PFO with analysis of the latest trials evaluating catheter-based closure of PFO’s for cryptogenic stroke. We also review the current evidence examining the use of antiplatelet medications versus anticoagulants for stroke prevention in those patients with PFO who do not qualify for closure per current guidelines.

Download Full-text

UCP 2 gene polymorphisms in obesity and diabetes, and the role of UCP 2 in cancer

FEBS Letters ◽

10.1002/1873-3468.13546 ◽

2019 ◽

Vol 593 (18) ◽

pp. 2525-2534 ◽

Cited By ~ 4

Author(s):

Jinran Li ◽

Rihua Jiang ◽

Xianling Cong ◽

Yunfeng Zhao

Keyword(s):

Gene Polymorphisms ◽

Obesity And Diabetes

Download Full-text

Role of Candidate Gene Variants in Modulating the Risk and Severity of Alcoholic Hepatitis

Alcoholism Clinical and Experimental Research ◽

10.1111/acer.14581 ◽

2021 ◽

Author(s):

James J. Beaudoin ◽

Tiebing Liang ◽

Qing Tang ◽

Bubu A. Banini ◽

Vijay H. Shah ◽

...

Keyword(s):

Candidate Gene ◽

Alcoholic Hepatitis ◽

Gene Variants

Download Full-text

Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19—The Role of RAGE-RAS Crosstalk

Biomolecules ◽

10.3390/biom11060876 ◽

2021 ◽

Vol 11 (6) ◽

pp. 876

Author(s):

Sara Chiappalupi ◽

Laura Salvadori ◽

Rosario Donato ◽

Francesca Riuzzi ◽

Guglielmo Sorci

Keyword(s):

Gene Polymorphisms ◽

Renin Angiotensin System ◽

Molecular Target ◽

Advanced Glycation ◽

Angiotensin System ◽

Major Player ◽

Glycation End Products ◽

End Products ◽

And Oxidative Stress

The receptor for advanced glycation-end products (RAGE) is a multiligand receptor with a role in inflammatory and pulmonary pathologies. Hyperactivation of RAGE by its ligands has been reported to sustain inflammation and oxidative stress in common comorbidities of severe COVID-19. RAGE is essential to the deleterious effects of the renin–angiotensin system (RAS), which participates in infection and multiorgan injury in COVID-19 patients. Thus, RAGE might be a major player in severe COVID-19, and appears to be a useful therapeutic molecular target in infections by SARS-CoV-2. The role of RAGE gene polymorphisms in predisposing patients to severe COVID-19 is discussed.

Download Full-text